Sichuan Kelun Pharmaceutical (002422) Q3 2026 earnings summary

Executive summary

• Q3 revenue was ¥4.274bn, up 1.93% YoY; net income attributable to shareholders was ¥339.3m, up 69.60%.

• 9M revenue was ¥13.113bn, down 1.24% YoY; attributable net income rose 22.18% to ¥1.467bn, while adjusted attributable net income fell 7.48% to ¥1.061bn.

Financial highlights

• 9M operating cash flow increased 62.46% YoY to ¥2.737bn, with settlement proceeds and higher bill discounting cited as drivers.

• 9M non-operating income reached ¥711.1m versus ¥4.6m a year earlier, mainly reflecting settlement proceeds; income tax expense fell 49.40% to ¥204.5m, partly due to a subsidiary tax refund.

• Total assets were ¥43.032bn at Sept. 30, up 8.03% from year-end; parent-attributable equity was ¥25.993bn, up 7.30%.

Key financial ratios and metrics

• Basic and diluted EPS were ¥0.21 in Q3, up 75.00% YoY; 9M EPS was ¥0.92, up 22.67%.

• Weighted average ROE was 1.32% for Q3, up 0.49 percentage points YoY, and 5.91% for 9M, up 0.73 percentage points.